Close Menu

NEW YORK (GenomeWeb) – Researchers at the University of California, San Diego have been awarded funding to develop a panel of extracellular RNA biomarkers for non-invasive glioma brain tumor diagnosis.

The research is being conducted in the lab of Bob Carter, a professor and chief of neurosurgery at UC San Diego Health System and a researcher in UCSD's Center for Theoretical and Applied Neuro-Oncology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The General Data Protection Regulation has slowed some data sharing with non-European researchers as they find ways to comply with the law, ScienceInsider reports.

A bioethicist from Abertay University uses a utilitarian approach to justify genetically modifying the human germline, the BBC reports.

The US has upgraded its network of public health labs to provide whole-genome sequencing to track antibiotic-resistant bacteria, Quartz reports.

In Science this week: approach to visualize 3D genome structure in single cells, RNA interference knockdown screens to examine genetic origins of beetle horns and insect wings,  and more.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
04
Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).